Circulating plasma surfactant protein type B as biological marker of alveolar-capillary barrier damage in chronic heart failure

Circulation: Heart Failure

Volumn 2, Issue 3, 2009, Pages 175-180

  Magrì, Damiano ^a,b   Brioschi, Maura ^a   Banfi, Cristina ^a   Schmid, Jean Paul ^a,d   Palermo, Pietro ^a   Contini, Mauro ^a   Apostolo, Anna ^a   Bussotti, Maurizio ^a   Tremoli, Elena ^a   Sciomer, Susanna ^a,c   Cattadori, Gaia ^a   Fiorentini, Cesare ^a   Agostoni, Piergiuseppe ^a,e  

^a UNIVERSITY OF MILAN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d BERN UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alveolar capillary barrier damage; Cardiopulmonary exercise test; Chronic heart failure; Lung diffusion; Surfactant protein B

Indexed keywords

CARBON MONOXIDE; SURFACTANT PROTEIN B;

ADULT; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CIRCULATION; CONTROLLED STUDY; DIFFUSION; FEMALE; HEART FAILURE; HUMAN; IMMUNOBLOTTING; LUNG DIFFUSION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG VENTILATION; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; CAPILLARY PERMEABILITY; CARBON DIOXIDE; CASE-CONTROL STUDIES; CHRONIC DISEASE; DIFFUSION; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PREDICTIVE VALUE OF TESTS; PULMONARY ALVEOLI; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B; PULMONARY VENTILATION; RESPIRATORY FUNCTION TESTS; UP-REGULATION;

EID: 72849145826     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.819607     Document Type: Article

References (37)

1. Chua TP, Coats AJS. The lungs in chronic heart failure. Eur Heart J. 1995; 16:882- 887.
2. Wright RS, Levine MS, Bellamy PE, Simmons MS, Batra P, Stevenson LW, Walden JA, Laks H, Tashkin DP. Ventilatory and diffusion abnormalities in potential heart transplant recipients. Chest. 1990; 98:816-820.
3. Agostoni PG, Cattadori G, Guazzi M, Palermo P, Bussotti M, Marenzi G. Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. Am Heart J. 2000; 140:E24.
4. Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koike A, Lubarsky L, Agostoni PG. Lung function and exercise gas exchange in chronic heart failure. Circulation. 1997; 96:2221-2227. (Pubitemid 27425826)
5. Guazzi M, Pontone G, Brambilla R, Agostoni PG, Rèina G. Alveolarcapillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur Heart J. 2002; 23:467- 476.
6. Guazzi M, Marenzi GC, Alimento M, Contini M, Agostoni PG. Improvement of alveolar capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 1997; 95:1930-1936.
7. Agostoni PG, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J. 2005; 26:159-164.
8. Koike A, Wasserman K, McKenzie DK, Zanconato S, Weiler-Ravell D. Evidence that diffusion limitation determines oxygen uptake kinetics during exercise in humans. J Clin Invest. 1990; 86:1698-1706.
9. Puri S, Baker BL, Dutka DP, Oakley CM, Hughes JM, Cleland JG. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure: its pathophysiological relevance and relationship to exercise performance. Circulation. 1995; 91:2769-2774.
10. Agostoni PG, Bussotti M, Palermo P, Guazzi M. Does lung diffusion impairment affect exercise capacity in patients with heart failure? Heart. 2002; 88:453- 459.
11. Huang YC, Helms MJ, Maclntyre NR. Normal values for single exhalation diffusing capacity and pulmonary capillary blood flow in sitting, supine position, and during mild exercise. Chest. 1994; 105:501-506.
12. Roughton FJW, Forster RE. Relative importance of diffusion and chemical reaction rate in determining rate of exchange of gases in the human lung, with special references to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. J Appl Physiol. 1957; 2:290-302.
13. Harris P, Heath D. Structural Changes in the Lung Associated With Pulmonary Venous Hypertension. Oxford, UK: Churchill Livingstone; 1986:329-344
14. Agostoni PG, Guazzi M, Bussotti M, Grazi M, Palermo P, Marenzi G. Lack of improvement of lung diffusion capacity following fluid withdrawal by ultrafiltration in chronic heart failure. J Am Coll Cardiol. 2000; 36:1600-1604.
15. Agostoni PG, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006; 27:2538-2543.
16. De Pasquale CG, Arnolda LF, Doyle IR, Aylward PE, Chew DP, Bersten AD. Plasma surfactant protein-B. A novel biomarker in chronic heart failure. Circulation. 2004; 110:1091-1096.
17. Cole FS. Surfactant protein B: unambiguously necessary for adult pulmonary function. Am J Physiol Lung Cell Mol Physiol. 2003; 285: L540-L542.
18. Serrano AG, Perez-Gil J. Protein-lipid interaction and surface activity in the pulmonary surfactant system. Chem Phys Lipids. 2006; 141:105-118.
19. De Pasquale CG, Arnolda LF, Doyle IR, Grant RL, Aylward PE, Bersten AD. Prolonged alveolocapillary barrier damage after acute cardiogenic pulmonary edema. Crit Care Med. 2003; 31:1060-1067.
20. De Pasquale CG, Arnolda LF, Doyle IR, Aylward PE, Russel AE, Bersten AD. Circulating surfactant protein-B levels increase acutely in response to exercise-induced left ventricular dysfunction. Clin Exp Pharmacol Physiol. 2005; 32:622- 627.
21. Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic heart failure. Am J Cardiol. 1985; 55:22A-31A.
22. 2. Eur Heart J. 2000; 21:154-161.
23. Chua TP, Ponikowski P, Harrington D, Anker SD, Webb-Peploe K, Clark AL, Poole-Wilson PA, Coats AJ. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997; 29:1585-1590. (Pubitemid 27272454)
24. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, Sperfeld A, Gläser S. Impairment of ventilatory efficacy in heart failure: prognostic impact. Circulation. 2000; 101:2803-2809.
25. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, Guazzi M. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007; 115:2410-2417.
26. Schaegger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987; 166:368-379.
27. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991; 144: 1202-1218.
28. Quanjer PH, Tammelling GJ, Cotes JE. Standardized lung function testing. Eur Respir J. 1993; 6:1-99.
29. Beaver WR, Wasserman K, Whipp BJ. A new method for detecting the anaerobic threshold by gas exchange. J Appl Physiol. 1986; 60: 2020-2027.
30. Piepoli MF, Corrà U, Agostoni PG, Belardinelli R, Cohen-Solal A, Hambrecht R, Vanhees L. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendation for performance and interpretation. I. Definition of cardiopulmonary exercise testing parameters for appropriate use in chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2006; 13:150-164.
31. Klein JM, Thompson MW, Snyder JM, George TN, Whitsett JA, Bell EF, McCray PB Jr, Nogee LM. Transient surfactant protein B deficiency in a term infant with severe respiratory failure. J Pediatr. 1998; 132:244-248.
32. Dempsey JA, Wagner PD. Exercise induced arterial hypoxemia. J Appl Physiol. 1999; 87:1997-2006.
33. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001; 104: 429-435.
34. Sun XG, Hansen JE, Garatachea N, Storer TW, Wasserman K. Ventilatory efficiency during exercise in healthy subjects. Am J Respir Crit Care Med. 2002; 166:1443-1448.
35. 2 slope in chronic heart failure. Eur J Cardiovasc Prevent Rehab. 2003; 10:267-272.
36. + transport is dependent on beta2-adrenergic receptor signalling. Circ Res. 2004; 94:1091-1100.
37. Agostoni PG, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, Palermo P, Fiorentini C. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail. 2007; 9:827- 833.